Concerns about anti-angiogenic treatment in patients with glioblastoma multiformeJoost J.C. Verhoeff, Wouter R. van Furth, Olaf van Tellingen et al.|BMC Cancer|2009Cited by 193
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON TrialC. Mircea S. Tesileanu, Martin J. van den Bent, Sanjeev Gill et al.|Clinical Cancer Research|2022Cited by 74
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic gliomaC. Mircea S. Tesileanu, Pim J. French, Martin J. van den Bent et al.|Neuro-Oncology|2021Cited by 66
Phase 1/2A Study of Glutathione Pegylated Liposomal Doxorubicin (2B3-101) in Patients with Brain Metastases (Bm) from Solid Tumors or Recurrent High Grade Gliomas (Hgg)Dieta Brandsma, Philippe Aftimos, Bojana Milojkovic Kerklaan et al.|Annals of Oncology|2014Cited by 33
Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON TrialC. Mircea S. Tesileanu, Martin J. van den Bent, Marc Sanson et al.|Unknown|2023Cited by 0